Intervacc AB
STO:IVACC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Intervacc AB
EPS (Diluted)
Intervacc AB
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Intervacc AB
STO:IVACC
|
EPS (Diluted)
kr0
|
CAGR 3-Years
34%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
EPS (Diluted)
kr3
|
CAGR 3-Years
-4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
EPS (Diluted)
kr2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
EPS (Diluted)
-kr37
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
EPS (Diluted)
kr1
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
19%
|
|
|
BioArctic AB
STO:BIOA B
|
EPS (Diluted)
kr11
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Intervacc AB
Glance View
Intervacc AB engages in the development of novel veterinary vaccines. The company is headquartered in Hagersten, Stockholm and currently employs 15 full-time employees. The company went IPO on 2017-04-07. The company develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The firm operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. The company offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
See Also
What is Intervacc AB's EPS (Diluted)?
EPS (Diluted)
-0.3
SEK
Based on the financial report for Dec 31, 2025, Intervacc AB's EPS (Diluted) amounts to -0.3 SEK.
What is Intervacc AB's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
10%
Over the last year, the EPS (Diluted) growth was 69%. The average annual EPS (Diluted) growth rates for Intervacc AB have been 34% over the past three years , 10% over the past five years .
